We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD (RANGE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00634023
First Posted: March 12, 2008
Last Update Posted: March 11, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
This is a cross-sectional study of symptom burden and clinical management. A subset of patients who have attended the Primary Care (PC) office with reflux symptoms during a retrospective period of 4 months (Index Visit) are invited to complete health survey questionnaires and partake in a subject-physician/study nurse interview (Visit 1), in order to assess the type, intensity and frequency of GERD symptoms at both visits and describe the treatment provided. Additionally, the impact of GERD on subjects' life, productivity and willingness to pay for GERD symptom relief will be explored. This design will give a "real-life" clinical practice picture in a representative population of PC doctors and subjects.

Condition
GERD

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: A Cross-Sectional, Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With Gastroesophageal Reflux Disease (GERD) RANGE: Retrospective ANalysis of GErd

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To describe the impact of reflux symptoms on subjects' daily life [ Time Frame: Assessed by means of the patient reported outcomes (PROs) ]

Secondary Outcome Measures:
  • To describe the impact of reflux symptoms on work productivity [ Time Frame: Assessed by means of the patient reported outcomes (PROs) ]

Estimated Enrollment: 500
Study Start Date: January 2008
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects attending PC offices with reflux symptoms. Subjects must not have participated in any other clinical study in the time window between the Index Visit and Visit 1.
Criteria

Inclusion Criteria:

  • Provision of informed consent
  • Ability to complete PRO instruments (non-applicable to "non-attendees")
  • Subject with GERD symptom(s). At least presence of troublesome heartburn and/or regurgitation even if not specifically recorded at the Index Visit.
  • At least one visit during the Retrospective Visit Period (-6 to -2 months prior to study start).

In the reasons for the Index Visit section of the medical record mention of acid regurgitation and/or heartburn symptom(s) or GERD diagnosis or GERD complications has to be explicit or a treatment decision (prescription) in a previously diagnosed subject although no mention of symptoms is made.

Exclusion Criteria:

  • Prophylactic PPI use to reduce the risk of ulcers in subjects being treated with NSAIDs
  • PPI treatment to heal an ulcer induced by NSAID treatment
  • PPI treatment for H-pylori eradication
  • Participation in any other clinical study in the time window between the Index Visit and Visit 1
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00634023


Locations
Canada, Alberta
Research Site
Edmonton, Alberta, Canada
Research Site
Spruce Grove, Alberta, Canada
Canada, British Columbia
Research Site
North Vancouver, British Columbia, Canada
Canada, Nova Scotia
Research Site
Windsor, Nova Scotia, Canada
Canada, Ontario
Research Site
Cornwall, Ontario, Canada
Research Site
Exeter, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Kanata, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Nepean, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Research Site
North Bay, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
St Catharines, Ontario, Canada
Research Site
Woodstock, Ontario, Canada
Sponsors and Collaborators
AstraZeneca
  More Information

ClinicalTrials.gov Identifier: NCT00634023     History of Changes
Other Study ID Numbers: D9612L00113
First Submitted: March 5, 2008
First Posted: March 12, 2008
Last Update Posted: March 11, 2009
Last Verified: March 2009

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases